Testing a new cell therapy for hard-to-treat lupus

Plain-English translation of NCT07432334 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This is a Phase I trial testing CD19 CAR-T cell therapy—a cutting-edge treatment that uses your own immune cells, modified in the lab to better fight lupus. Researchers will collect some of your T cells, reprogram them to target the B cells that are causing lupus problems, then infuse them back into your body. The trial is looking at whether this treatment is safe and whether it helps people whose lupus hasn't improved with standard medications.

Lupus is an autoimmune disease where the body attacks its own tissues, and for some patients, standard drugs don't work well enough. This medication takes a very different approach—instead of just suppressing the immune system, it targets the specific B cells responsible for lupus, which may offer a longer-lasting solution for people who haven't benefited from other treatments.

Do you qualify?

You likely qualify if…

you are between 16 and 55 years old
you have been diagnosed with systemic lupus erythematosus (SLE) with moderate to severe disease
your lupus has not improved after at least 6 months of standard treatments, including corticosteroids, hydroxychloroquine, and other immunosuppressive drugs
you have positive lupus antibodies (ANA, anti-dsDNA, or anti-Sm) on recent testing or in your medical history
your liver, heart, and lung function are adequate (measured by specific blood tests and breathing tests)
your blood cell counts are adequate without ongoing growth factor support

You likely don't qualify if…

you have a history of serious brain disorders, seizures, or bleeding conditions
you have had a heart attack, severe heart failure, or uncontrolled heart problems in the past 3 months
you have a kidney transplant or severe asthma requiring long-term treatment
you have an active infection such as hepatitis B or C, HIV, tuberculosis, or CMV
you are currently taking certain medications (such as anti-CD2 therapies) before cell collection

What participation looks like

If you join this trial, you will first undergo a procedure called leukapheresis to collect some of your T cells (this takes a few hours). Your cells will then be sent to the lab to be modified and grown over several weeks. Before receiving the treatment, you'll receive a short chemotherapy regimen to prepare your immune system. Then you'll receive a single intravenous infusion of your modified cells and stay in the hospital for close monitoring. You'll have frequent follow-up visits and blood tests over an extended period to watch for side effects and track how well the treatment is working.

AI-generated summary from trial data · Jul 10, 2026 · Not medical advice

Testing a new cell therapy for hard-to-treat lupus

What is this trial?

Do you qualify?

What participation looks like

Trial locations